Nanobiotix S.A. (NBTX)
NASDAQ: NBTX · Real-Time Price · USD
3.100
-0.180 (-5.49%)
Dec 20, 2024, 4:00 PM EST - Market closed
Nanobiotix Employees
Nanobiotix had 102 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
102
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$443,335
Profits / Employee
-$351,620
Market Cap
158.11M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
ModivCare | 21,200 |
The Joint | 794 |
Adaptimmune Therapeutics | 449 |
Sutro Biopharma | 302 |
Seres Therapeutics | 233 |
Cellectis | 221 |
Pro-Dex | 148 |
Corbus Pharmaceuticals Holdings | 19 |
NBTX News
- 4 days ago - NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024 - GlobeNewsWire
- 12 days ago - NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer - GlobeNewsWire
- 5 weeks ago - NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms - GlobeNewsWire
- 7 weeks ago - NANOBIOTIX to Participate in Multiple Investor Conferences in November - GlobeNewsWire
- 3 months ago - NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results - GlobeNewsWire
- 3 months ago - NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth - GlobeNewsWire
- 3 months ago - Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 6 months ago - NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024 - GlobeNewsWire